SUMMARY Acebutolol ('Sectral'), a cardioselective beta-blocking drug, was administered intravenously in a dose of 25 mg to 10 patients with congestive cardiomyopathy. All of them were in a stable condition on antifailure regimens. The drug resulted in a statistically significant decline in left ventricular contractility as judged by peak left ventricular dP/dT and the contractility index. The mean aortic blood pressure also fell. There was a significant increase in end-diastolic and end-systolic left ventricular volumes.
Congestive cardiomyopathy is generally regarded as a syndrome caused by diverse aetiological agents (Connolly et al., 1976) . In the majority of cases the cause is unknown and current treatment grossly inadequate. Goodwin (1974) has stated that, 'at the present time the prognosis for severe congestive cardiomyopathy is so bleak and the treatment so unsatisfactory that cardiac transplantation may be considered in desperate cases'. Waagstein et al. (1975) reported clinical improvement in 7 patients with congestive cardiomyopathy who were given oral beta-blocking drugs. These drugs were judged to have resulted in improvement on the basis of clinical signs, ergometricallymeasured exercise capacity, and non-invasive tests of cardiac function. No haemodynamic data were presented. Since a priori, beta-receptor blockade should result in worsening of cardiac function in such patients, this was a paradoxical finding. It has major implications in the therapeutic management and pathophysiology of congestive cardiomyopathies as well as the action of beta-blocking agents.
This communication reports a haemodynamic study of 10 patients with congestive cardiomyopathy in whom beta-blockade was produced by the intravenous administration of a cardioselective beta-blocker, acebutolol ('Sectral').
Received for publication 27 November 1978 Subjects and methods Ten patients were studied, 8 men and 2 women. The clinical and electrocardiographic findings together with medication at the time of study are listed in Table 1 . The diagnosis of congestive cardiomyopathy was based on the criteria outlined by Goodwin and Oakley (1972) .
Coronary artery disease, pericardial, valvular, and congenital heart disease were excluded by right and left heart catheterisation, angiocardiography, and selective coronary angiography. No patient was or had been hypertensive. Secondary cardiomyopathies were excluded by appropriate tests and infiltrative cardiac muscle lesions by haemodynamic studies and endomyocardial biopsy.
All patients had had at least one episode of frank congestive cardiac failure resulting from cardiac muscle dysfunction. The first 5 patients had not been in clinical cardiac failure for at least 1 month before study. The remaining 5 patients had suffered cardiac decompensation within this period. All were on antifailure regimens at the time of study, and none was in clinical failure. (Sparling et al., 1960) .
Quantitative left ventriculography was next performed in the 30°right anterior oblique projection by injecting 50 ml meglumine ('Renografin') at a rate of 10 to 15 ml/s through an 8 French 'Pigtail' catheter introduced retrogradely across the aortic valve. Acebutolol ('Sectral'), 25 (1) Left ventricular volumes Left ventricular end-systolic and end-diastolic volumes were measured from the 30°right anterior oblique left ventriculogram by a special-purpose calculator (Bones and Ikram, 1977 (Diamond et al., 1971 ). Compliance at end-(9) Left ventricular compliance diastole was calculated from the formula In this study it was assumed that the left ventricular pressure-volume curve was exponential (Noble et dV/VdP (mmHg') = dV/dP x 1/V. al., 1969; Gaasch et al., 1972 ) and conformed to:
Pbkv. hscnas ewitnk(n-n) Statistical analysis was performed by Student's P =bekv. This can also be written k=(InP Inb)/ et V. In the formula P is the left ventricular end-paired t test. diastolic pressure, V is the end-diastolic volume Results (ml/m2), b is the extrapolated left ventricular pressure at zero V, is the slope of the log P-V The results are detailed in Tables 2 and 3 . relation, and e is the base of the natural logarithm.
The constant b cannot be measured easily in (1) HEART RATE humans so it was assumed to be the same as that There was an overall fall of 8 per cent in heart rate derived from animal studies, that is 0A43 mmHg. after acebutolol. This was not statistically significant. (2) EJECTION FRACTION The ejection fraction fell by 8 per cent, this change again being statistically insignificant.
(3) END-DIASTOLIC VOLUME There was a significant increase in end-diastolic volume of 10 per cent (P < 0 01).
(4) END-SYSTOLIC VOLUME This was increased by 21 per cent which was highly significant (P < 0005).
( 
Discussion
Acebutolol is a cardioselective beta-blocking drug with one-quarter to one-seventh the beta-blocking potency of propranolol (Lewis et al., 1973) . It also possesses intrinsic sympathomimetic activity. Hence it has similar pharmacological properties to alprenolol and practolol which were used by Waagstein et al. (1975) in their oral treatment of patients with congestive cardiomyopathy. The dose of 25 mg was chosen because the haemodynamic response to 30 mg intravenously has been reported in normal subjects (Lewis et al., 1973) . Left ventricular contractility as judged by peak dP/dT and V max fell by 16 per cent and 14 per cent, respectively. There was little change in mean arterial pressure (2% fall) or left ventricular end-diastolic pressure (5% rise). Waagstein et al. (1975) attributed much of the observed therapeutic benefit in their patients to a reduction of heart rate. They postulated that since left ventricular external work is equivalent to the product of heart rate and systolic blood pressure, a reduction in the former would reduce work load and also permit better diastolic filling.
The mean pretreatment heart rate was higher and the magnitude of the fall after treatment (19%) was greater than in our series (8%). This may be because their patients were deteriorating whereas ours were clinically stable. Premedication with atropine in our cases may also have contributed to the smaller fall in rate. None the less, beta-blockade results in some reduction in cardiac rate which may be beneficial. The majority of our patients showed an increase in end-diastolic and end-systolic left ventricular volumes after beta-blockade, with a small reduction in systolic ejection fraction. These changes indicate a negative inotropic effect. They are in contrast to the observations of Waagstein et al. (1975) who noted a progressive reduction in radiographic cardiac size after beta-blockade. There are several inherent problems in the measurement of cardiac volumes by angiography, and they are accentuated in these patients with their very large and poorly contracting left ventricular silhouettes. However, non-angiographic radiological methods have also shown an increase in the heart size of normal subjects after beta-blockade (Chamberlain, 1966) .
Stroke volume increased in 3 patients and fell in 7, the overall change being a fall of 3 per cent. This was not statistically significant nor was the 10 per cent fall in cardiac index. Waagstein et al. (1975) speculated that a reduction in tachycardia would allow better diastolic filling and thus increase stroke volume. Our results indicate that this does happen in some patients, but the increase is small and unpredictable.
Myocardial contractility as judged by peak rate of rise of left ventricular pressure fell significantly in all but 2 cases. This is in keeping with the well-known effects of beta-blocking drugs. Left ventricular stroke work showed some fall with betablockade, but the results were not statistically significant. Stroke work per unit of end-diastolic volume ('contractility index'), another measure of myocardial contractility, showed a significant fall. These findings indicate a decline in contractility. Since cardiomyopathic patients already suffer from impaired contractility, it is arguable that betablockade would be harmful. On the other hand, since contractility is a major determinant of myocardial energy requirements, a decrease would reduce the heart's energy needs.
The systemic arterial blood pressure fell in all patients, the fall being highly significant statistically. Waagstein et al. (1975) also reported a fall in blood pressure 3 to 7 days after oral beta-blockade. Since systolic arterial pressure is a determinant of myocardial energy needs, a fall would diminish the work load of the left ventricle.
Left ventricular compliance has been shown to be reduced in patients with congestive cardiomyopathy (Gaasch et al., 1972) . The effect of betablockade on compliance in these patients has not been previously reported. Though there are several practical and theoretical problems in the measurement of compliance, this study suggests that betablockade may improve compliance. This tends to improve filling and reduce end-diastolic pressure. Waagstein et al. (1975) quote the prolonged bedrest regimen of McDonald et al. (1972) in support of their hypothesis that reduction of myocardial work is of therapeutic benefit. These authors put patients with congestive cardiomyopathy to bed for periods ranging from an average of 73 to 239 days. They observed relief of symptoms and a reduction in heart size which was proportional to the duration and degree of bed rest. Our study confirms that beta-blockade decreases most of the determinants of cardiac work, that is rate, systolic blood pressure, and contractility. However, in our experience, these theoretically beneficial changes are accompanied by further cardiac dilatation and decline in contractility -an apparent worsening of the basic defects in congestive cardiomyopathy.in congestive cardiomyopathy. blockade beta-adrenergic receptor
